Stockwatch: Mistaken Acquisitions Dim Earnings Season
Executive Summary
Fourth-quarter earnings reports from J&J, Novartis, AbbVie and Biogen all missed on sales but more worryingly, lower sales from some recent acquisitions contributed to the missed expectations. The time from child star to problem child seems to be shorter than I remember.
You may also be interested in...
Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So
Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.
Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing
CEO pledges transparency and responsible pricing of J&J drugs during the company’s earnings call, while outlining its goals for US health care and tax reform. Fourth quarter performance was unspectacular, although J&J's oncology and immunology portfolios showed sales growth.
Emicizumab Data Has Shire And Novo Looking Over Their Shoulders
Positive data from the HAVEN 1 Phase III study of Genentech's emicizumab put pressure on the hemophilia franchises of both Shire and Novo Nordisk.